This inventor holds 4 USPTO granted patents and 3 EPO patents. Top assignees: Daegu-Gyeongbuk Medical Innovation Foundation, National Cancer Center, Omic Smap Inc.. Active years: 2020-2026.
Location History:
- Yongin-si, KR (2020)
- Daegu, KR (2021)
Company Filing History:
3 out of 10 
1 out of 263 
1 out of 1 
Years Active: 2020-2026
Title: Eunmi Hong: Innovator in Pharmaceutical Compounds
Introduction
Eunmi Hong is a notable inventor based in Daegu, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target various diseases. With a total of two patents to his name, his work focuses on innovative solutions for treating protein kinase-related diseases and cancer.
Latest Patents
Eunmi Hong's latest patents include a pyrrolo-pyrimidine derivative compound and an imidazopyridine derivative. The pyrrolo-pyrimidine derivative is designed to prevent or treat protein kinase-related diseases. This compound exhibits outstanding inhibitory activity against LRRK2 kinase and has been verified to inhibit various protein kinases, making it a promising candidate for therapeutic applications. The imidazopyridine derivative, on the other hand, is aimed at preventing or treating cancer. It effectively inhibits cancer-related kinases and has shown potential in promoting cancer cell apoptosis in various models.
Career Highlights
Eunmi Hong has worked with esteemed organizations such as the Daegu-Gyeongbuk Medical Innovation Foundation and the National Cancer Center. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Eunmi has collaborated with notable colleagues, including Hwan Geun Choi and Jung Beom Son. Their joint efforts have further advanced the research and development of innovative pharmaceutical compounds.
Conclusion
Eunmi Hong's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to addressing critical health challenges. His work continues to pave the way for new treatments that can significantly impact patient care.